Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Johnson & JohnsonNYSE: JNJ

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income declines year over year

Q3 FY2026 net income of $210M fell 95.9% year over year, behind the -35.9% change in trailing-twelve-month net income. Sequentially, it fell 96.2% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.

Context

  • Net income amounted to 28.5% of revenue in FY2025, up 12.6 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 16 analysts of $27.15B (+1.3%) for the fiscal year ending Dec 2026, a slowdown from the +90.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$210M-96.2% QoQ
Last fiscal yearDec 2025
$26.8B+90.6% YoY
LTMSep 2026
$16.1B-35.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-95.9%+39.4%+135.3 pp
1 year+90.6%+1.3%-89.3 pp
3-year CAGR+14.3%+7.9%-6.4 pp
5-year CAGR+9.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
26.8B USD
Year-over-year change
+90.6%
4-year CAGR
+6.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How JNJ compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.9% is the 8th highest of 11, against a peer median of +4.5%.
  • Net income amounts to 16.2% of revenue for JNJ, versus a peer median of 17.1%.
JNJ Competitors
Net Income for JNJ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.4%+32.5%22.9%
AZNAstraZeneca PLCLTM Sep 2026$11.82B USD+15.4%+59.9%19.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$9.27B USD+83.1%+3.6%18.9%
AMGNAmgen Inc.LTM Jun 2026$8.74B USD+32.1%+5.6%22.9%
ABBVAbbVie Inc.LTM Jun 2026$6.32B USD+66.4%-29.1%9.8%
GSKGSK plcLTM Jun 2026£5.62B GBP+41.0%+0.6%16.9%
GILDGilead Sciences, Inc.LTM Jun 2026$5.24B USD-17.0%+22.8%17.2%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
SNYSanofiLTM Jun 2026€3.96B EUR-46.8%-11.2%8.1%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding JNJ) —+4.5%+4.6%17.1%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income20.88B17.94B13.33B14.07B26.8B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
Deferred Income Tax(2.08B)(1.66B)(4.19B)(2.18B)1.54B
Stock-Based Compensation1.14B1.14B1.16B1.18B1.35B
Change in Working Capital(4.24B)(4.01B)2.51B1.84B(12.72B)
Accounts Receivables(2.4B)(1.29B)(624M)(406M)(1.78B)
Inventory(1.25B)(2.53B)(1.32B)(1.13B)(1.45B)
Accounts Payables2.44B1.1B2.35B1.62B2.38B
Other Working Capital(3.03B)(1.29B)2.11B1.75B(11.86B)
Other Non-Cash Items324M819M2.5B2.03B49M
Operating Cash Flow23.41B21.19B22.79B24.27B24.53B
Capital Expenditures(3.65B)(4.01B)(4.54B)(4.42B)(4.83B)
Acquisitions (Net)(60M)(17.65B)358M(15.15B)(17.54B)
Purchases of Investments(30.39B)(32.38B)(10.91B)(1.73B)(920M)
Sales of Investments25.01B41.61B19.39B2.46B1.66B
Other Investing Activities417M65M(3.42B)235M(1.96B)
Investing Cash Flow(8.68B)(12.37B)878M(18.6B)(23.59B)
Debt Repayment(990M)7.45B(2.73B)10.05B9.64B
Common Stock Issued004.24B00
Common Stock Repurchased(3.46B)(6.04B)(5.05B)(2.43B)(5.95B)
Dividends Paid(11.03B)(11.68B)(11.77B)(11.82B)(12.38B)
Other Financing Activities1.43B1.39B(508M)1.07B3.16B
Financing Cash Flow(14.05B)(8.87B)(15.83B)(3.13B)(5.54B)
Effect of Forex Changes(178M)(312M)(112M)(289M)201M
Net Change in Cash502M(360M)7.73B2.25B(4.4B)
Free Cash Flow19.76B17.19B18.25B19.84B19.7B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.